Sign in

CIK 0001472012 · Non-accelerated filer

Immunome Inc.

Sign in to watch
Ticker
IMNM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
770694340
Phone
610-321-3700
Business address
18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$334,224
in 1 filing, $334K under 10b5-1 plans

Net −$334,224. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Higgins Jack −$334K Chief Scientific Officer sold 17% of stake

Reading 56 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2024-02-20 Horn Kinney CHIEF BUSINESS OFFICER Grant or award · Stock option (right to buy) +300,000 300,000
2024-01-31 Rosett Max EVP, OPERATIONS & INTERIM CFO Grant or award · Stock option (right to buy) +175,000 175,000
2024-01-31 Stoneman Sandra G. CHIEF LEGAL OFFICER & GC Grant or award · Stock option (right to buy) +200,000 200,000
2024-01-02 SCHAFER CAROL Director Grant or award · Stock option (right to buy) +32,934 32,934
2023-12-13 Roberts Phil Noland Chief Technology Officer Grant or award · Stock option (right to buy) +275,000 275,000
2023-12-01 Higgins Jack Chief Scientific Officer Grant or award · Stock option (right to buy) +200,000 200,000
2023-11-07 BIENAIME JEAN JACQUES Director Grant or award · Stock option (right to buy) +40,696 40,696
2023-10-27 Barchas Isaac Director Grant or award · Stock option (right to buy) +41,538 41,538
2023-10-27 Boylan James P Director Grant or award · Stock option (right to buy) +41,538 41,538
2023-10-27 Lechleider Robert Chief Medical Officer Grant or award · Stock option (right to buy) +400,000 400,000
2023-10-02 SIEGALL CLAY B President and CEO Purchase +169,204 $5.91 $1000K 319,636
2023-10-02 Turner Bruce Chief Strategy Officer Purchase +42,300 $5.91 $250K 42,300
2023-10-02 PRENDERGAST FRANKLYN G Director Grant or award +60,840 60,840
2023-10-02 PRENDERGAST FRANKLYN G Director Grant or award · Stock Option (Right to Buy) +137,725 $1.35 $186K 137,725
2023-10-02 RAPP MICHAEL Director Grant or award +253,806 $5.91 $1.5M 1,071,172
2023-06-08 RAPP MICHAEL Director Grant or award · Stock Option (Right to Buy) +6,500 6,500
2023-06-08 Stoneman Sandra G. General Counsel and CLO Grant or award · Stock Option (Right to Buy) +56,000 56,000
2023-06-08 Roche Corleen M. Chief Financial Officer Grant or award · Stock Option (Right to Buy) +58,000 58,000
2023-06-08 ROBINSON MATTHEW K Chief Technology Officer Grant or award · Stock Option (Right to Buy) +58,000 58,000

Page 8 of 8 · 159 trades